Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 19/20 | 0.60 |
| ▸ | PAK3 | O75914 | 1/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.49 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.49 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.49 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035063 | 0.88 | TNK2 (0.59) | TNK2PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15035922 | 0.82 | TNK2 (0.56) | TNK2PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15035834 | 0.82 | TNK2 (0.55) | TNK2PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15237036 | 0.79 | CDK4 (0.52) | TNK2 | |
| SCHEMBL16309179 | 0.79 | TNK2 (0.52) | TNK2PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15034960 | 0.79 | TNK2 (0.57) | TNK2PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15035716 | 0.76 | TNK2 (0.52) | TNK2PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL13553729 | 0.76 | TNK2 (0.54) | TNK2PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15035576 | 0.76 | TNK2 (0.56) | TNK2PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15034888 | 0.75 | CDK4 (0.51) | TNK2PAK3PAK1PAK2PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK5 | TNK2 10/4885PAK3 2/4885PAK4 5/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | TNK2 7/4885PAK3 6/4885PAK4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.